Hospira Beats Analyst Estimates on EPS
Hospira (NYS: HSP) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Hospira met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share increased. GAAP earnings per share increased.
Margins grew across the board.
Hospira reported revenue of $1.03 billion. The 11 analysts polled by S&P Capital IQ hoped for revenue of $1.03 billion on the same basis. GAAP reported sales were 0.7% lower than the prior-year quarter's $1.03 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.55. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.51 per share. Non-GAAP EPS of $0.55 for Q2 were 7.8% higher than the prior-year quarter's $0.51 per share. GAAP EPS were $0.20 for Q2 against -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 31.1%, 260 basis points better than the prior-year quarter. Operating margin was 5.4%, 140 basis points better than the prior-year quarter. Net margin was 3.2%, 340 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $990.8 million. On the bottom line, the average EPS estimate is $0.45.
Next year's average estimate for revenue is $4.06 billion. The average EPS estimate is $2.04.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 138 members out of 167 rating the stock outperform, and 29 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Hospira a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $33.14.
Add Hospira to My Watchlist.
The article Hospira Beats Analyst Estimates on EPS originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.